Literature DB >> 18256553

Specialized centers and systems for heart attack care.

Dean J Kereiakes1.   

Abstract

Evidence from randomized controlled clinical trials and registries suggest that primary percutaneous coronary intervention provides superior clinical outcomes when compared with fibrinolytic therapy for the treatment of ST segment elevation myocardial infarction (STEMI). However, the delivery of expert and timely primary percutaneous coronary intervention to the majority of patients with STEMI is extremely challenging. This objective has fueled the concept of regional centers of excellence for the care of patients with STEMI as well as regional STEMI networks similar to those currently available for trauma or stroke victims. This article reviews the rationale behind, as well as the issues inherent to, the development of systems of care for STEMI patients.

Entities:  

Mesh:

Year:  2008        PMID: 18256553     DOI: 10.1111/j.1751-7168.2008.07644.x

Source DB:  PubMed          Journal:  Am Heart Hosp J        ISSN: 1541-9215


  3 in total

1.  Diurnal, weekly and seasonal variations of chest pain in patients transported by emergency medical services.

Authors:  Ziad Faramand; Stephanie O Frisch; Christian Martin-Gill; Parker Landis; Mohammad Alrawashdeh; Khaled A Al-Robaidi; Clifton W Callaway; Salah S Al-Zaiti
Journal:  Emerg Med J       Date:  2019-07-31       Impact factor: 2.740

2.  Opportunities for achieving resuscitation goals during the inter-emergency department transfer of severe sepsis patients by emergency medical services: A case series.

Authors:  Adam Froehlich; Ryan J Tegtmeier; Brett A Faine; Jennifer Reece; Azeemuddin Ahmed; Nicholas M Mohr
Journal:  J Crit Care       Date:  2019-04-19       Impact factor: 3.425

3.  Regional disparities in mortality after ischemic heart disease in a Brazilian state from 2006 to 2010.

Authors:  Luciano de Andrade; Vanessa Zanini; Adelia Portero Batilana; Elias Cesar Araujo de Carvalho; Ricardo Pietrobon; Oscar Kenji Nihei; Maria Dalva de Barros Carvalho
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.